Levodopa

CAS 59-92-7 14 current records 4 historicalSmall Molecule

Who holds supplier records for Levodopa? 14 organisations hold a current record for Levodopa: an active US FDA Type II Drug Master File or a CEP. A further 4 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (6), India (4), Japan (1), United States (1) and 1 other country (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Levodopa: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/levodopa

Reading the evidence

  • 14 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Levodopa expires 21 Oct 2033. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (14)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Levodopa. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Levodopa sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (11)

Certificates of Suitability on the EDQM register for Levodopa, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 16 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
AJINOMOTO CO., INC. Chuo-KuJP
CEP 1999-001 - Rev 02
Levodopa
Aug 2026—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2017-090 - Rev 05
Levodopa, Micronised I, micronised II and non-micronised
Apr 2026Inspected May 2026
Italy
ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO. LTD. TaizhouCN
CEP 2024-527 - Rev 00
Levodopa
Dec 2025—
ZHEJIANG WILD WIND PHARMACEUTICAL CO., LTD. Geshan TownCN
CEP 2021-195 - Rev 01
Levodopa, Enzymatic process
Oct 2025—
SHANDONG LUKANG PHARMACEUTICAL CO., LTD. Jining CityCN
CEP 2022-202 - Rev 00
Levodopa
Apr 2025—
TAPI NL B.V. AmsterdamNL
CEP 1999-187 - Rev 10
Levodopa
Mar 2025—
HETERO DRUGS LIMITED HyderabadIN
R0-CEP 2022-320 - Rev 00
Levodopa
Mar 2023—
SHANDONG XINHUA PHARMACEUTICAL CO., LTD. ZiboCN
R1-CEP 2009-174 - Rev 02
Levodopa
Apr 2022—
MAITHRI DRUGS PRIVATE LIMITED Bonthapally VillageIN
R0-CEP 2020-161 - Rev 00
Levodopa
Mar 2022—
GUANGXI BONGER PHARMACEUTICAL CO., LTD. Tiandong TownCN
R1-CEP 2014-348 - Rev 00
Levodopa
Sept 2021—
DIVI'S LABORATORIES LIMITED HyderabadIN
R1-CEP 2005-161 - Rev 04
Levodopa
Jan 2018—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (4)

Organisations whose Type II DMFs for Levodopa are no longer active. These show a past filing, not current supply.

Show all 4 historical records
  • India · Inactive DMF 25498 · filed Nov 2011
  • Hungary · Inactive DMF 12505 · filed May 1997
  • PFC ITALIANA SRL DIV ALFA CHEMICALS ITALIANA
    Inactive DMF 8444 · filed Oct 1989
  • LILLY RESEARCH LABORATORIES DIV ELI LILLY AND CO
    Inactive DMF 1367 · filed May 1969

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (1 listed product contain Levodopa). The latest listed patent expires 21 Oct 2033. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Levodopa is a precursor to the neurotransmitter dopamine used to treat Parkinson's disease and dopamine-responsive dystonia. It is often combined with a peripheral decarboxylase inhibitor like carbidopa to increase its effectiveness.

Chemical identity

IUPAC name
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
Canonical SMILES
C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
InChIKey
WTDRDQBEARUVNC-REOHCLBHSA-N
Synonyms
L-DOPA

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Aromatic Amino Acid
Chemical structure
Aromatic

Therapeutic areas

NeurologyMovement Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Levodopa?

14 organisations hold an active US FDA Type II Drug Master File or a CEP for Levodopa: AJINOMOTO CO INC (Japan), SHANDONG XINHUA PHARMACEUTICAL CO LTD (China), Divis Laboratories (India), MAITHRI DRUGS PRIVATE LTD (India), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), Zhejiang Wild Wind Pharmaceutical Co.,Ltd. (China), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD (China) and Acella Pharmaceuticals, LLC (United States), and 6 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Levodopa Drug Master Files are active?

AJINOMOTO CO INC (DMF 12379, 31654), SHANDONG XINHUA PHARMACEUTICAL CO LTD (DMF 22598, 44214), Divis Laboratories (DMF 17874), MAITHRI DRUGS PRIVATE LTD (DMF 35312), Zhejiang Huahai Pharmaceutical Co., Ltd. (DMF 31612), Zhejiang Wild Wind Pharmaceutical Co.,Ltd. (DMF 27938), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO LTD (DMF 40608) and Acella Pharmaceuticals, LLC (DMF 32057) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Levodopa records mean?

4 organisations have only inactive Type II DMFs for Levodopa. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Levodopa have a European Certificate of Suitability?

Yes. 11 organisations hold a valid CEP for Levodopa on the EDQM register, including AJINOMOTO CO., INC. Chuo-Ku (JP), ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. Taizhou (CN), ZHEJIANG YONGTAI CHIRAL MEDICINE TECHNOLOGY CO. LTD. Taizhou (CN), ZHEJIANG WILD WIND PHARMACEUTICAL CO., LTD. Geshan Town (CN), SHANDONG LUKANG PHARMACEUTICAL CO., LTD. Jining City (CN) and TAPI NL B.V. Amsterdam (NL) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Levodopa?

Yes. The latest patent listed for an approved US product containing Levodopa expires 21 Oct 2033, across 1 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Levodopa supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Levodopa?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.